Orexo Ab · OMXSTO:ORX
Orexo Ab — DNB Carnegie Small Cap Day 2026
15 slides from Orexo Ab's conference presentation, Aug 31, 2026
Slide 1: DNB Carnegie
orexo . ‘Rooted _ . in science, proven in market eS mere RAN a ee ~ DNB Carnegie August 31, 2026
Slide 2: Legal disclaimer
2 Legal disclaimer • This presentation, which is personal to the recipient, has been prepared and produced by Orexo AB (publ) (“Orexo”) solely for the benefit of investment analysis and may not be used for any purpose other than assessment of investments concerning Orexo. Unless otherwise stated, Or
Slide 3: Investment highlights
3 Investment highlights Transitioning to a scalable drug delivery platform model 01 Proven ability to develop, commercialize, and monetize assets 02 Platform validated across multiple molecules and delivery routes 03 Pipeline targeting growing USD 4 bn+ markets with clear business development pathwa
Slide 4: This is Orexo
4 This is Orexo Comments Q2 Net Revenue LTM 1 Over 30 years of experience and successful development of four products launched in >25 markets in multiple international partnerships. can transform with strong Innovative pipeline with Engineered for scale – drug delivery evidence in nasal delivery nea
Slide 5: Orexo's journey: from product to platform
5 Orexo’s journey: from product to platform 1 2 3 Divestment of Streamlining Transformation Building a new company on a strong heritage Zubsolv US rights the operations Zubsolov US rights sold to Restructure organisation 4 drugs developed from Long experience from Markets Drive global leadership ide
Slide 6: AmorphOX technology is today the foundation of Orexo
6 AmorphOX® technology is today the foundation of Orexo 8 years of development >SEK 500 million investment Patent protection from 2039-2047
Slide 7: 3 strategic focus areas to maximize value of the AmorphOX technology
7 3 strategic focus areas to maximize value of the AmorphOX technology New applications of the AmorphOX® technology are EXPLORE key to unlocking substantial future value creation Generating proof of concept in obesity/GLP-1 agonist and vaccines Proprietary projects drive greater value capture DEVELO
Slide 8: Development pipeline and launched products
8 Development pipeline and launched products1 Partnership Development program Technology /collaboration Preclinical Clinical Registration Approved Exploratory/ OX472 GLP-1 agonist, semaglutide Large molecules Vaccine, influenza Own projects/ OX390, atipamezole, overdose Small molecules caused by adu
Slide 9: OX640 aiming for best-in-class nasal epinephrine emergency treatment of severe allergic reactions
9 OX640 aiming for best-in-class nasal epinephrine emergency treatment of severe allergic reactions Planned to enter pivotal clinical trials in Q4 2026 Differentiated OX640 target product profile Solid preliminary PK data2 from cross-study vis-à-vis nasal competitors: comparison lower risk in clinic
Slide 10: Izipry (registration phase) batches ready for stability and reliability studies
10 Izipry (registration phase) batches ready for stability and reliability studies Manufacturing of required batches at commercial scale initiated completed - ainscalable Q4 2025drug delivery platform • Process initiated to complete the FDA required testing with expected resubmission in 2026. • Stab
Slide 11: OX390 – Developed with BARDA - US Health Department and Human Services
11 OX390 – Developed with BARDA - US Health Department and Human Services • OX390 (preclinical) targets adulterated overdoses where naloxone/nalmefene are less effective • Addresses a high-mortality population, supporting first responders • Built on AmorphOX®, aligned with Orexo’s broader platform a
Slide 12: Orexo "Explore" AmorphOX in semaglutide (obesity) and vaccines
12 Orexo “Explore” AmorphOX in semaglutide (obesity) and vaccines Promising Preclinical AmorphOX Successful formulation of three types PK study: formulations of vaccines • Intranasal Oral tablet • SARS-CoV-2 Spike Protein stability at 40 °C for semaglutide 7x 3 months with AmorphOX • Live Attenuated
Slide 13: Business development an important source of financing
13 Business development an important source of financing 1 Zubsolv® divestment of USD 91 m plus earn-out Dec 2025 2 Research contribution from BARDA of up to USD 51 m Financing 3 Royalties from commercial products Zubsolv, Abstral® and Edluar® 4 Divestment of the development programs Izipry and OX64
Slide 14: Drive value through innovation and growth
14 Drive value Ideas through For Vision And Mission Ppt Presentations innovation and growth Several near term opportunities for significant value growth Partner OX640 and IzipryTM Expand AmorphOX® partnerships Expand into new growth areas to reduce cost and risks with AmorphOX® • OX640 potential to
Slide 15: Thanks
Thanks www.orexo.com www.orexo.com Orexo is headquartered in Uppsala, Sweden, with a US subsidiary in New Jersey. The company has been listed on Nasdaq Stockholm’s IR@orexo.com main market since 2005 (STO: ORX) and trades as ADRs on the OTCQX market in the US (OTCQX: ORXOY).